bpc-157 clinical trials humans safety Regeneration or Risk? A Narrative Review of for Musculoskeletal Healing bpc-157 human clinical trials evidence bpc-157 clinical trials humans safety

The key advantages of therapeutic peptides include their high potency, selectivity, minimum side effects, specificity for their target receptors, minimal drug-drug interactions, and reduced immunogenicity [1]

The result is functional tissue organized fibers with tensile strength rather than disorganized scar (musculoskeletal repair)

However, the medication discontinuation rates were greater than 50% across all doses compared to 40% with placebo, with the most common adverse events (AE) being gastrointestinal in nature [27]

To my knowledge, there is only one study on humans and it's not a clinical trial

As always, consulting with a healthcare professional is crucial before considering tesofensine or any other pharmaceutical intervention